Dr.Gregory K. Bell is quoted in this article published by BioPharm International about the regulatory and legal issues associated with bringing recent biosimilars and biobetters to market. Click below to read the article.
CAR-T vs. bispecific therapies: Two growth stories are reshaping hematologic oncology
While both CAR-T cell therapies and bispecific antibodies have experienced rapid growth in recent years, new analysis by CRA’s Chris Nüesch suggests that the...
